STOCK TITAN
  1. Home
  2. News
  3. ANRO

Alto Neuroscience Inc. - $ANRO STOCK NEWS

Welcome to our dedicated page for Alto Neuroscience news (Ticker: $ANRO), a resource for investors and traders seeking the latest updates and insights on Alto Neuroscience stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alto Neuroscience's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alto Neuroscience's position in the market.

News
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
Rhea-AI Summary
Alto Neuroscience, Inc. (NYSE: ANRO) announces positive Phase 1 results for ALTO-101, a novel PDE4 inhibitor developed for cognitive impairment associated with schizophrenia. The study showed improved pharmacokinetics and tolerability with a transdermal delivery system, reducing adverse events. The company plans a proof-of-concept study for CIAS in 2024, with topline data expected in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.76%
Tags
clinical trial
-
News
Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder
Rhea-AI Summary
Alto Neuroscience, Inc. (NYSE: ANRO) initiates Phase 2 study for ALTO-203 in major depressive disorder patients with anhedonia, showing positive emotional and cognitive effects in Phase 1 trials. The study aims to evaluate its antidepressant potential.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
clinical trial
-
News
Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights
Rhea-AI Summary
Alto Neuroscience, Inc. (ANRO) reported positive Phase 2a results for ALTO-100 and ALTO-300, highlighting response prediction using their Precision Psychiatry Platform™. The company is on track with patient enrollment for Phase 2b MDD studies. They successfully completed an oversubscribed IPO, with a cash position of $210 million as of February 29, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.41%
Tags
earnings
News
Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors
Rhea-AI Summary
Alto Neuroscience, Inc. (NYSE: ANRO) appoints Dr. Maha Radhakrishnan, an experienced industry executive, to its board of directors. Dr. Radhakrishnan brings decades of expertise in product development and global medical strategy from leading biotechnology and pharmaceutical companies. Her appointment signifies Alto's commitment to advancing precision psychiatry and personalized patient care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.74%
Tags
management
-
News
Alto Neuroscience to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Alto Neuroscience, Inc. (ANRO) announced its participation in upcoming investor conferences, including Jefferies Biotech on the Bay Summit, UBS Virtual CNS Day, and Stifel 2024 Virtual CNS Days. Dr. Amit Etkin, the CEO, will be engaging in one-on-one meetings and fireside chats during the conferences, providing investors with valuable insights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.71%
Tags
conferences
-
News
Alto Neuroscience to Present at the TD Cowen 44th Annual Healthcare Conference
Rhea-AI Summary
Alto Neuroscience, Inc. (ANRO) CEO Amit Etkin to present at TD Cowen 44th Annual Healthcare Conference. The presentation will be available via live webcast and replay for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.21%
Tags
conferences
News
Alto Neuroscience Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Rhea-AI Summary
Alto Neuroscience, Inc. (ANRO) closed its upsized initial public offering of 9,246,000 shares of common stock, raising approximately $147.9 million. The offering price was $16.00 per share, with underwriters exercising their option to purchase 1,206,000 additional shares. Alto's common stock is listed on the NYSE under the ticker symbol ANRO. Jefferies, TD Cowen, Stifel, and William Blair were the joint book-running managers for the offering, while Baird acted as the lead manager. Registration statements were filed with the SEC and became effective on February 1, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.11%
Tags
IPO offering
-
News
Alto Neuroscience Announces Pricing of Upsized Initial Public Offering
Rhea-AI Summary
Alto Neuroscience, Inc. (NYSE: ANRO) has announced the pricing of its upsized initial public offering of 8,040,000 shares of common stock at a public offering price of $16.00 per share. The aggregate gross proceeds are expected to be approximately $128.6 million before deducting underwriting discounts and commissions. The company has also granted the underwriters a 30-day option to purchase up to an additional 1,206,000 shares of common stock at the initial public offering price. The offering is expected to close on February 6, 2024, subject to customary closing conditions. Jefferies, TD Cowen, Stifel, and William Blair are acting as joint book-running managers for the offering, with Baird as the lead manager. The shares are expected to begin trading on the New York Stock Exchange on February 2, 2024 under the ticker symbol 'ANRO'.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
IPO offering
Stock ANRO logo
Alto Neuroscience Inc.

NYSE:ANRO

ANRO Rankings

#3195 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

ANRO Stock Data

403.53M
16.23M
13.11%
37.25%
8.91%
Biotechnology
Healthcare
Link
United States of America
LOS ALTOS